Clinical Scorecard: Impact of Prior Metformin Administration on Outcomes in Diabetic Patients with Sepsis: A Systematic Review and Meta-Analysis

At a Glance

Key Highlights

• Preadmission metformin use is associated with significantly reduced overall mortality in diabetic sepsis patients (OR 0.58).
• Significant mortality reductions observed at 28-day, 90-day, 365-day, and in-hospital time points.
• Metformin use correlates with improved serum creatinine levels but elevated serum lactate.

Guideline-Based Recommendations

Diagnosis

• Consider history of metformin use as a prognostic indicator in diabetic patients presenting with sepsis.

Management

• Integrate metformin use history into clinical decision-making and sepsis management bundles.
• Continue evaluation of metformin’s potential protective effects in diabetic sepsis patients.

Monitoring & Follow-up

• Monitor serum creatinine and lactate levels in diabetic sepsis patients with prior metformin use.

Risks

• Be aware of elevated serum lactate associated with metformin use, though clinical significance requires further study.

Patient & Prescribing Data

Diabetic patients hospitalized with sepsis

Preadmission metformin use is linked to lower mortality and improved renal function markers, supporting its consideration in treatment history.

Clinical Best Practices

• Assess metformin use history in diabetic sepsis patients as part of risk stratification.
• Incorporate metformin history into antimicrobial stewardship and sepsis bundle protocols.
• Recognize metformin’s immunomodulatory and organ-protective effects as potential adjunctive benefits.
• Encourage further large-scale randomized controlled trials to confirm metformin’s efficacy in sepsis outcomes.

References

• Global diabetes statistics 2024
• Sepsis epidemiology and pathophysiology
• Metformin mechanisms and effects
• Meta-analysis on metformin and sepsis mortality